Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection

Vascular Pharmacology(2024)10.1016/j.vph.2024.107288Source: DataRank Database

12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection is a research paper published in Vascular Pharmacology (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 2.82)OA: greenTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Priscilla Ajala,Coleton Jordan,James Mintz,Rodger D. MacArthur ORCID,Simone Kennard ORCID

Live enrichment

PubMed:38428626 PMC:PMC11189738 OpenAlex:https://openalex.org/W4392247389

National Heart Lung and Blood Institute

Grant: 1R01HL155265-01

National Heart Lung and Blood Institute

Grant: 1R01-HL-13 0301-01

National Heart Lung and Blood Institute

Grant: 1R01-HL-147639-01A1

American Heart Association Inc

Grant: 21PRE830396

NIAMS NIH HHS

Grant: R01 AR082307

NHLBI NIH HHS

Grant: R01 HL147639

NHLBI NIH HHS

Grant: R01 HL155265

NHLBI NIH HHS

Grant: R01 HL130301

American Heart Association Inc

National Heart Lung and Blood Institute

National Institute on Aging

FWCI

2.82

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11189738/pdf/nihms-1972672.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1537189124000132?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1537189124000132?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11189738

Fields of Study

HIV-related health complications and treatmentsHIV Research and TreatmentHIV/AIDS Research and InterventionsAnimalsEnergy MetabolismMaleMice, TransgenicPiperazinesHIV InfectionsOxazinesPyridonesHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsDisease Models, AnimalMiceUncoupling Protein 1VasodilationBody WeightAdipose Tissue, BrownMice, Inbred C57BLDolutegravir

MeSH Terms

Uncoupling Protein 1DolutegravirAnimalsBody WeightAdipose Tissue, BrownDisease Models, AnimalEnergy MetabolismHeterocyclic Compounds, 3-RingMaleMice, Inbred C57BLMice, TransgenicOxazinesPiperazinesPyridonesVasodilationHIV InfectionsHIV Integrase InhibitorsMice

Keywords

EndocrinologyInternal medicineAdipose tissueBrown adipose tissueLean body massCachexiaThermogeninAdipogenesisChemistryImmunologyBiologyMedicineBody weightObesityHIVIntegrase inhibitorEndothelial functionCombination Antiretroviral Therapy

Sustainable Development Goals

SDG 0: Affordable and clean energy

12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection

FAIR Checklist

Authors (8)

Funding (11 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)